Stay updated with breaking news from Waheed Jamal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Phase III trial shows that adults hospitalised for acute heart failure were 36 percent more likely to experience a clinical benefit if initiated on empagliflozin.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardiance® (empagliflozin) for the treatment of adults with symptomatic chronic heart failure, Boehringer Ingelheim and Eli Lilly and Company announced today.1
- The positive opinion is based on the landmark EMPEROR-Preserved Phase III trial, which showed significant outcomes in patients with heart failure with left ventricular ejection fraction over 40%1 If
In a new sub-analysis of the landmark EMPEROR-Preserved Phase III trial, empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure and slowed kidney
This new indication is based on the EMPEROR-Reduced trial, which showed a significant 25 per cent reduction in the combined relative risk versus placebo of...